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Abstract
Background
Severe acute exacerbations (AE) of idiopathic pulmonary fibrosis (IPF) are medically
untreatable and often fatal within days. Recent evidence suggests autoantibodies may be
involved in IPF progression. Autoantibody-mediated lung diseases are typically refractory
to glucocorticoids and nonspecific medications, but frequently respond to focused autoanti-
body reduction treatments. We conducted a pilot trial to test the hypothesis that autoanti-
body-targeted therapies may also benefit AE-IPF patients.
Methods
Eleven (11) critically-ill AE-IPF patients with no evidence of conventional autoimmune dis-
eases were treated with therapeutic plasma exchanges (TPE) and rituximab, supplemented
in later cases with intravenous immunoglobulin (IVIG). Plasma anti-epithelial (HEp-2) auto-
antibodies and matrix metalloproteinase-7 (MMP7) were evaluated by indirect immunofluo-
rescence and ELISA, respectively. Outcomes among the trial subjects were compared to
those of 20 historical control AE-IPF patients treated with conventional glucocorticoid thera-
py prior to this experimental trial.
Results
Nine (9) trial subjects (82%) had improvements of pulmonary gas exchange after treatment,
compared to one (5%) historical control. Two of the three trial subjects who relapsed after
only five TPE responded again with additional TPE. The three latest subjects who re-
sponded to an augmented regimen of nine TPE plus rituximab plus IVIG have had sus-
tained responses without relapses after 96-to-237 days. Anti-HEp-2 autoantibodies were
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present in trial subjects prior to therapy, and were reduced by TPE among those who re-
sponded to treatment. Conversely, plasma MMP7 levels were not systematically affected
by therapy nor correlated with clinical responses. One-year survival of trial subjects was
46+15% vs. 0% among historical controls. No serious adverse events were attributable to
the experimental medications.
Conclusion
This pilot trial indicates specific treatments that reduce autoantibodies might benefit some
severely-ill AE-IPF patients. These findings have potential implications regarding mecha-
nisms of IPF progression, and justify considerations for incremental trials of autoantibody-
targeted therapies in AE-IPF patients.
Trial Registration
ClinicalTrials.gov NCT01266317
Introduction
Idiopathic pulmonary fibrosis (IPF) is an almost invariably fatal disease with a median survival
of3 years.[1] IPF patients typically experience slowly progressive, if somewhat episodic, lung
function deterioration. Nonetheless, a sizeable proportion of these patients, variously estimated
as 10-to-50% or more, develop acute exacerbations (AE) that can result in respiratory failure
and death within days.[2] No medical treatment has been shown to benefit AE-IPF patients.
[1,2]
Although the pathogenesis of IPF is generally considered to be enigmatic,[1] B-cell abnor-
malities that are widely regarded as pathological and pathognomonic in recognized autoim-
mune syndromes such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)
are also prevalent in IPF patients.[3–21] Focal B-cell accumulations in diseased organs are a
prototypic characteristic of chronic adaptive immune responses to antigen(s).[22] These tissue
lymphocytes not only produce antibodies (and autoantibodies), but also have numerous other
immunopathogenic effects due to their elaborations of proinflammatory and vasoactive media-
tors.[23] Abnormal aggregates of B-cells are similarly common in IPF lungs, particularly in
proximity to fibroproliferative lesions.[3–5,18–20] C-X-C motif chemokine 13 (CXCL13) is a
key mediator of pathological B-cell trafficking to inflammatory foci.[24] Moreover, circulating
levels of this mediator are often increased proportionately to the clinical activity of convention-
al autoimmune disorders.[24–27] The abnormal B-cell accumulations within damaged IPF
lungs also appear to result from intrapulmonary production of CXCL13, and circulating levels
of this chemokine are analogously increased and correlated with IPF manifestations, such as
acute exacerbations and deaths.[18,20] Tissue deposits of antigen-antibody (immune) com-
plexes and activated complement are highly injurious mediators of autoantibody productions
in other immunological diseases,[28] and these abnormalities are also near ubiquitous in IPF
lungs.[5,12,18] Increased proportions of B-cells are differentiated in patients with autoanti-
body-mediated disorders, including SLE, RA and Sjogren’s syndrome, due to repetitive interac-
tions of the lymphocytes with autoantigens.[23,29,30] Similar findings are present in IPF
patients, and the magnitude of their B-cell differentiation is correlated with the severity of their
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lung disease.[19] Circulating levels of B-lymphocyte stimulator factor (BLyS), a trophic factor
critically necessary for B-cell survival and antibody production, are increased proportionately
to disease activity in SLE, RA and other classical autoimmune syndromes.[31–33] BLyS levels
are also abnormally increased in the pulmonary airspaces [21] and circulation of IPF patients,
[19] and concentrations of the latter are associated with disease manifestations, including oc-
currences of acute exacerbations and mortality.
The production of antibodies with avidities for varied self-proteins is a common feature of
immunological disorders, as well as being a defining criterion of “autoimmunity”.[34] Numer-
ous distinct autoantibodies have been found in IPF cohorts,[7–17] and one or more of these
self-reactive immunoglobulins are present in80% of these patients.[8,12] Several specific au-
toantibodies have been shown to exert deleterious functional and cytopathic effects, and/or are
highly associated with clinical manifestations and outcomes of IPF patients, including the de-
velopment of acute exacerbations.[9–14,16,17]
Based on these reports,[3–21] and additional unpublished data, we hypothesized that auto-
antibodies may play a role in the progression of IPF. Other autoantibody-mediated lung dis-
eases can also manifest with acute pulmonary dysfunction in the absence of extrinsic causes.
[35–39] Lung histology in these acute cases is typified by the superimposed presence of diffuse
alveolar damage, which is also a characteristic finding of AE-IPF.[2] The clinical presentations
of these acute autoantibody lung syndromes are frequently indistinguishable from AE-IPF
cases, and they are also resistant in most cases to treatment with glucocorticoids and nonspecif-
ic medications, again like IPF. Conversely, however, the conventional autoimmune lung disor-
ders are often responsive to mechanistically-focused therapies that reduce autoantibodies.[35–
39] A corollary of our hypothesis is that similar specific therapies might, thus, also have efficacy
for AE-IPF. Accordingly, we conducted a pilot study of autoantibody-targeted treatments in
critically-ill AE-IPF patients. The results of the trial indicate autoantibody-reductive therapies
may benefit some patients with this otherwise refractory and highly lethal syndrome.
Methods
The protocol for this trial and supporting TREND checklist are available as supporting infor-
mation; see S1 TREND Checklist and S1 Protocol.
Trial Subjects
Trial subjects were recruited by solicitation from among patients admitted to specialized, high-
level respiratory care units between April 2011 and October 2013 at the University of Pitts-
burgh Medical Center (UPMC) (n = 10) or the University of Texas Medical Branch (UTMB)
in Galveston, TX (n = 1).
All subjects fulfilled current consensus diagnostic criteria for IPF.[1] AE were defined by
worsening hypoxemia and dyspnea within the preceding 30 days, characteristic new radio-
graphic pulmonary infiltrates on chest CT scans obtained at hospital admission, and no other
evident cause of respiratory dysfunction after thorough clinical assessments.[2]
These clinical assessments included comprehensive, replicate, and serial evaluations of his-
torical features, physical exam findings, and laboratory data by health care teams that included
experienced, specialized pulmonary medicine attending physicians, in addition to the trial in-
vestigators. The protocol for this study permitted the addition of specific autoantibody reduc-
tion modalities to standard clinical care. Standard routine tests included analyses of sputum for
bacteria, fungi and respiratory viruses, blood and urine cultures, and urinary legionella antigen
tests (and all of these were negative in the subjects). Other diagnostic tests were ordered by at-
tending physicians, based on their assessments of the individual patients.
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Respiratory function was too tenuous to safely permit invasive diagnostic procedures in all
but two of the spontaneously breathing subjects (Subjects #8 and #11), in whom bronchoscopy
with bronchoalveolar lavage (BAL) were performed. BAL was also performed in the three intu-
bated and mechanically ventilated patients (Subjects #1,#5,#10). Studies conducted on the BAL
returns were similar to those performed in the sputum specimens, and were similarly all nega-
tive. CT angiograms to exclude pulmonary emboli were performed in Subjects #1, #2, #6, and
#8, and lower extremity Doppler venous studies to exclude in situ thromboses were obtained in
Subjects #10 and #11. Preserved left ventricular function [e.g., that could not account for
congestive heart failure or pulmonary edema] was found on cardiac ultrasounds performed in
all subjects except #2 and #5, and corroborated by left heart catheterizations with pressure mea-
surements in Subjects #3 and #7-#9).
Due to the novelty of these therapies, enrollment was limited to extremely-ill patients with
rapidly progressive AE who were expected to die within days. None of the subjects were candi-
dates for lung transplantations at their presentations.
Exclusion criteria included histories, clinical findings, or laboratory evidence of convention-
al autoimmune syndromes after careful evaluations that included an extensive panel of autoim-
mune serologic tests performed in accredited hospital clinical laboratories.[12] Other exclusion
criteria for safety included a history of hepatitis B or C infection, prior adverse reaction to
blood products or trial medications, prior exposures to human-murine chimeric antibodies,
malignancy, ongoing treatment with a cellular immunosuppressant (e.g., cyclophosphamide,
methotrexate, mycophenolate, azathioprine, calcineurin inhibitors, etc.) or angiotensin con-
verting enzyme inhibitors, uncontrolled diabetes, hypertension or hypotension, uncorrectable
coagulopathies or thrombocytopenia, or concurrent participation in other experimental trials.
Subjects #1–7 were treated on a trial protocol approved by the Institutional Review Board
(IRB) at the University of Pittsburgh (U. Pitt). Experimental subjects (or their surrogates) pro-
vided written informed consent.
The trial was designed as a Phase I/II study to assess the feasibility and safety of this experi-
mental approach in severely ill IPF patients with acute exacerbations. The primary trial end-
points were compilations of respiratory deteriorations (defined by deteriorating gas exchange)
and hemodynamic deteriorations (defined as a need for medical intervention). The secondary
endpoint was 60 day survival or survival to lung transplantation during this interval, compared
to historical controls. Given the exploratory nature of this trial, statistical power analysis for
sample size was speculative at best. However, a sample size of 10 was adopted to expose a mini-
mum number of patients to potential risks of the experimental treatment while still obtaining
useful information relevant to design of a subsequent larger trial.
Following the conclusion of the trial, and influenced by results observed in that first cohort,
subjects #8–11 were treated under auspices of innovative medical practice (compassionate
care). These patients gave oral consent after being fully informed of potential adverse effects
and uncertain benefit with this regimen. There were no provisions for experimental blood sam-
pling in these patients. The inclusion and analyses of their deidentified clinical data were sanc-
tioned by additional protocols approved by the U. Pitt. and University of Texas Medical
Branch (UTMB) IRBs.
Historical Controls
Data were extracted from the Medical Archival Record System using a search query for patients
admitted to PUH-UPMC with diagnoses of idiopathic pulmonary fibrosis (CPT 516.3) or
post-inflammatory pulmonary fibrosis (CPT 515) during a two-year period prior to the imple-
mentation of the experimental trial. Their medical records were deidentified and reviewed in
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accordance with a protocol approved by the U. Pitt. IRB. The historical controls fulfilled the
same inclusion and exclusion criteria as trial subjects.
Experimental Treatments
Glucocorticoids were administered so as to not withhold “standard therapy” in the critically-ill
AE-IPF trial patients, despite a lack of evidence these agents are efficacious.[1,2] The first seven
subjects were treated with a conventional local regimen: methylprednisolone 1 gm i.v. on day
one, followed by 40 mg/day i.v. (or the oral predisone equivalent) for two weeks (excepting
rituximab treatment days), and then 20 mg i.v. (or prednisone equivalent) until day 28. The
subsequent four subjects were treated with the initial methylprednisolone bolus on day one,
but with a reduction of the subsequent daily doses to 20 mg/day of p.o. prednisone or equiva-
lent i.v. methylprednisolone, to minimize steroid-associated side effects, for a total of 21 days.
Therapeutic plasma exchanges (TPE) of 1.5x the estimated plasma volumes were performed
using albumin:saline (3:1), with 95–100% volume replacement. Prolongations of prothrombin
times due to TPE [40,41] were treated by adjusting the replacement fluid to include fresh fro-
zen plasma. Five (5) TPE were scheduled on treatment days 1,2,3,5 and 6 among the first seven
(7) trial subjects. In some cases (Subjects #5–7), up to six additional TPE were later performed
to treat clinical relapses. Based on interim consideration of clinical results, the number of
scheduled TPE treatments was increased to nine (9) in the four subsequent subjects (#8–11),
administered on days 1,2,3,5,6,9,11,13, and 15.
Rituximab 1 gm i.v. was administered to subjects after the fifth TPE (day 6), and either one
week later among the first cohort of seven subjects, or after the final TPE (day 15) among the
last four subjects. Premedications given prior to rituximab infusions were methylprednisolone
100 mg i.v., diphenydramine 50 mg i.v., and acetaminophen 650 mg p.o.
Intravenous immunoglobulin (IVIG) 0.5 mg/kg/day administrations were scheduled on
days 16–19 in the last four subjects.
HEp-2 Autoantibody Studies
Autoantibodies against HEp-2 cells were detected by indirect immunofluorescence assays
(IFA) in subjects #1–7, using previously described reagents and methods.[12] Plasma speci-
mens were obtained pretreatment, and on (±1) days 14, or at study termination or hospital dis-
charge, and tested for these autoantibodies at dilutions of 1:20, 1:40, 1:80, and 1:160. Prior
study had shown frequent false positive results among control normal plasmas at 1:10 dilu-
tions, and no previously tested IPF specimens were positive at>1:160. Specimens were scored
for the highest [most dilute] titer they were positive, determined as fluorescence intensity great-
er than healthy control plasmas.[12] Staining in all cases was nonspecific and distinct from the
particular florescence patterns that are diagnostic of conventional autoimmune syndromes.
[34]
Matrix Metalloproteinase 7 (MMP7)
MMP7 concentrations in the plasma samples were determined by ELISA, as previously de-
scribed.[42] MMP7 is a proteolytic enzyme involved in degradation of extracellular matrix,
and a possible mediator of IPF.[42] MMP7 determinations were performed in the plasma spec-
imens to examine treatment effects on concentrations of a representative soluble non-autoanti-
body mediator that has been linked to IPF.
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Ethics Statement
These protocols were approved by the University of Pittsburgh Investigational Review Board
and the University of Texas Medical Branch Investigational Review Board.
Statistics
Intergroup comparisons of continuous data were performed by Mann-Whitney. Dichotomous
variables were analyzed by chi-square, with odds ratios (OR) and 95% confidence intervals
(CI) established by logistic regression. Survival analyses were performed using product-limit
estimation and comparisons by log rank. Hazard ratios (HR) and 95% confidence intervals
(CI) were established by proportional hazard regression. Alpha values<0.05 were considered
significant. Statistical analyses were performed using StatView (SAS Institute, Cary, North Ca-
rolina). Unless otherwise denoted, data are depicted as means±SE.
Results
Subjects
Demographic and clinical characteristics of the AE-IPF trial subjects are outlined in Table 1.
They tended to be older (69±4 years) than historical controls (64±2 years) (p = 0.1). Males
comprised 91% of the trial subjects vs. 75% of the historical controls (p = 0.3). The trial subjects
all had substantial requirements for supplemental O2 at the time of their first experimental
treatment (Table 2), and only one (Subject #8) was able to perform formal pulmonary function
tests (e.g., spirometry and diffusing capacity determinations) prior to these treatments.
Of eighteen AE-IPF patients screened for the trial (Fig 1), two declined to participate, and
two others were not eligible due to a preexistent history of cancer or an unwillingness to fully
comply with treatments. Two other subjects withdrew from the study soon after giving in-
formed consent, but before their treatments, due to very rapid deteriorations and their unwill-
ingness to continue supportive medical care (e.g., intubation and institution of mechanical
ventilation). Given that the primary focus of this study was to examine feasibility and safety of
the treatment regimen, details of these subjects are not included in subsequent analyses, unless
otherwise denoted. All six of these screened but untreated subjects died within 30 days.
Another subject gave informed consent, after clinical evaluation and a favorable screening
review of recent medical tests performed at another institution. Repeat testing here, however,
with results that became available after experimental treatment had started, showed he had
positive autoantibody assays for antinuclear antigens and rheumatoid factor. This subject was
judged to be a protocol violation and was excluded from further study (Fig 1).
Clinical Observations
A priori intentions to measure gas exchange as arterial oxygen partial pressures (PaO2) while
subjects breathed 100% oxygen (FIO2 = 1.0) were precluded by the inabilities of many air-hun-
gry patients to tolerate the requisite tight-fitting face masks, and dependence of an early subject
on noninvasive (face mask) bi-level ventilator support (which confounds interpretations of
PaO2/FIO2). Nonetheless, all but two of the experimental trial subjects (#1 and #10) had obvi-
ous improvements of gas exchange after TPE treatments (Table 2), in distinction to effects of
conventional steroid therapy among historical controls (Fig 2A). Treatments among all the
spontaneously breathing subjects except #10 resulted in subjective reports of less dyspnea and
greater exertional tolerance. Maximal walk distances pre- and post-treatment were measured
in Subjects #7–11 (Fig 2B). Total lung capacity of Subject #8 increased from 41% of predicted
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Table 1. Demographic Characteristics and Prior Histories of Trial Subjects.
Subject Age Gender IPF Dx Comments
1 76 M 5 yr History of prior MI. AE onset 1 week prior to admission. Previous lung biopsy conﬁrmed UIP.
2 75 F 2
months
AE onset 5 days prior to admission.
3 52 M 2
months
Severe coronary artery disease. AE onset 3 weeks prior to admission. Previous lung biopsy conﬁrmed UIP.
4 81 M 3 yr AE onset 2 weeks prior to admission.
5 83 M 1 yr Precipitous AE over days (did not require supplemental O2 1 week prior to admission).
6 74 M 6
months
AE onset 2 weeks prior to admission.
7 56 M 1 yr Precipitous AE over days (did not require supplemental O2 1 week prior to admission). Later lung explant
conﬁrmed UIP.
8 81 M 2 yr AE onset <2 weeks earlier. Admitted for hospice placement.
9 52 M 2 yr Precipitous AE over days (did not require supplemental O2 1 week prior to admission).
10 61 M 1 yr AE onset 4 weeks earlier and accelerating.
11 71 M 2 yr AE onset 4 weeks earlier and accelerating. Previous lung biopsy conﬁrmed UIP.
Age denoted in years. IPF Dx denotes when the original IPF diagnosis was established in these subjects, prior to their admission for acute exacerbations.
AE = acute exacerbation; UIP = usual interstitial pneumonia.[1] Subjects were not listed for lung transplantation due to advanced age (Subjects #1,2,4–
6,8,11), irreparable coronary artery disease (#3), or being too acutely ill to undergo the extensive necessary pre-transplantation evaluations (#7,#9). The
AE-IPF in all subjects was rapidly progressive, with daily or near daily increases of hypoxemia and dyspnea. None had infections, congestive heart failure,
or other causes of pulmonary dysfunction aside from the AE-IPF (2).
doi:10.1371/journal.pone.0127771.t001
Table 2. Individual Treatment Outcomes.
# Pre-Rx O2 Post-Rx O2 Comments
1 FIO2 0.7PEEP 10 FIO2 1.0PEEP
10
Lung function worsened during treatment. Died on day 11 after recurrent MI.
2 FIO2 0.7PEEP 10 50% FM Despite improvement, her care was changed to comfort measures only at family request. She was
extubated successfully and treated with MS gtts.
3 15L NC 5L NC Less dyspnea and ambulating after treatment. Respiratory function remainedimproved post-
treatment. Died suddenly on day 76 (cause uncertain but likely cardiac).
4 10L NC 4L NC Less dyspnea and ambulating after treatment. Respiratory function remained improved post-
treatment for >365 days.
5 100% FM Bi-level positive
pressure by mask
5L NC Less dyspnea and ambulating after treatment. AE-IPF relapsed 3 days later and he required
intubation and mechanical ventilation. Repeated TPE x 5, with clinical response and was
successfully extubated to 5L NC. He insisted on eating but failed swallow study. He elected CMO
status and ate, aspirated, and transferred to SNF on MS gtts. Died on day 32.
6 60% FM Room Air Much less dyspnea and ambulating after treatment, and discharged from the hospital. Relapse on
day 27 and was treated again with 5x TPE, but did not respond. Died on day 40.
7 15L NCoxi Room Air Good response but disease recurred 2 d after completion of TPE x 5. Responded again to 6
additional TPE, and discharged to home on room air, where he remained until lung transplantation
on day 98.
8 10L NC 3L NC Doing well at home on day 237
9 15L NCoxi Room Air Discharged and returned to work. Awaiting transplant on day 137.
10 60% FM FIO2 0.7PEEP
10
Did not respond to TPE x 5 and rituximab x 1. Prostate cancer (Stage III) diagnosed by needle
biopsy after treatment initiated. Support withdrawn on day 15.
11 15L NCoxi 1L Discharged to rehabilitation facility. Now at home and doing well on day 96.
Pre and Post are relative to experimental treatment courses (Rx); O2 requirements denoted as that necessary to maintain resting arterial oxygen
saturations at 93%; MI = myocardial infarction; FM = face mask; NC = nasal cannula; NCoxi = nasal cannula with “oxymizer” reservoir; CMO = comfort
measures only; MS gtts = morphine sulfate infusion; TPE = therapeutic plasma exchange; SNF = skilled nursing facility.
doi:10.1371/journal.pone.0127771.t002
Acute IPF Exacerbation Therapy
PLOS ONE | DOI:10.1371/journal.pone.0127771 June 17, 2015 7 / 17
to 52% after therapy; respective measures of diffusing capacity also improved from 20% to 33%
of predicted. Clinical responses were also accompanied by radiographic improvements (Fig 3).
Despite clinical improvement of Subject #2, manifested by decreased requirement for sup-
plemental oxygen, successful removal from mechanical ventilation, and extubation, her medi-
cal power of attorney insisted on withdrawal from the study and institution of comfort
measures only. Three subjects experienced relapses after their initial course of five TPE (#5–7).
Repeat TPE again resulted in substantial improvement in two of these subjects (#5 and #7)
(Table 2). There have been no relapses among the three subjects (#8,#9,#11) who responded to
the augmented treatment regimen (nine TPE + rituximab + IVIG) (Table 2).
TPE was well-tolerated in spontaneously breathing patients. Short-term phenylephrine in-
fusions for transient hypotension were necessary in two of three subjects who had TPE during
mechanical ventilation (#1 and #2). Subject #6 developed intertriginous candida dermatitis,
possibly related to steroid therapy, which was successfully treated with anti-mycotic agents. In-
creased serum glucose levels (managed with short-term insulin administrations) were frequent
among the first cohort of seven subjects treated with the higher steroid dose regimen. There
were no adverse events attributable to the rituximab or IVIG.
Autoantibodies
Anti-HEp-2 autoantibodies were present prior to treatment in the eight subjects in whom
these immunoglobulins were assayed, and all among these except Subject #1 had reductions of
Anti-HEp-2 titers following TPE (Fig 4). Subject #1 was also notable for his refractoriness to
therapy. The two subjects with prolonged treatment responses after only five TPE (#3 and #4)
had lower initial anti-HEp-2 titers, as well as no detectable autoantibodies after treatment.
Fig 1. Flowchart of subject recruitments for these experimental trials.Original Regimen denotes the first
series of subjects who were treated with the initial, relatively more conservative regimen (#1–7). Augmented
Regimen denotes the most recent four subjects (#8–11) who received a more aggressive therapeutic course,
based on interval results in the first cohort (see text for details). TPE = therapeutic plasma exchange;
IVIG = intravenous immunoglobulin; * denotes oral consent of patients, under auspices of innovative clinical
practice, that were given by these patients after being fully informed of potential risks and yet-unproven
efficiencies of the novel treatments.
doi:10.1371/journal.pone.0127771.g001
Acute IPF Exacerbation Therapy
PLOS ONE | DOI:10.1371/journal.pone.0127771 June 17, 2015 8 / 17
MMP7
MMP7 levels were not consistently altered by TPE, nor overtly correlated with clinical re-
sponses (Fig 5).
Survival. Sixty (60) day survival of the experimental subjects was 55 ± 15%, compared to
20 ± 9% in the AE-IPF historical control group (HR = 0.35, 95% CI = 0.13–0.98, p = 0.035). Al-
though assessment of longer-term survival was not an a priori endpoint, the unexpectedly pro-
longed responses of many experimental trial subjects prompted us to compare survival over
longer intervals.
The aggregate experimental trial cohort had significantly better one-year survival than his-
torical controls (Fig 6A). Results to date also suggest the later, more aggressive treatment proto-
col (nine TPE + rituximab + IVIG), may result in more durable responses (Fig 6B).
These analyses included the first two trial subjects who were intubated at enrollment
(AE-IPF patients who require mechanical ventilation have singularly poor prognoses [2]), and
the subject with an underlying malignancy (discovered after the experimental treatment was
initiated), which would have been an exclusion criterion (cancer patients often develop refrac-
tory autoimmune syndromes [43]). The analyses here also included the two subjects who re-
ceived a treatment course, and responded to same, but nonetheless withdrew from the trial
protocol and further supportive medical care (#2 and #5) (Table 2).
Fig 2. Clinical Responses to Experimental Therapy. A.) Decreases in Supplemental Oxygen Requirements. Oxygen requirements decreased in only one
of the historical control subjects during their hospitalizations, whereas pulmonary gas exchange improved with experimental treatments among most of the
trial cohort (see also Table 2). B.) Changes in Abilities to Ambulate. Trial subjects who responded to experimental therapy reported improved exercise
tolerance, but maximal walk distances were added as a formal outcome assessment in latest subjects, identified here by subject number (see Tables 1 and
2). With the exception of Subject #10 who showed no response to the experimental treatment, the walk distances of these later patients increased
substantially. (Note: The post-treatment >2 mile distance of Subject #9 was limited by boredom rather than exercise capacity).
doi:10.1371/journal.pone.0127771.g002
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Inclusion of data from all eligible IPF patients (intent-to-treat), including the two enrolled
IPF subjects who did not receive a therapeutic course prior to their withdrawal (Fig 1) still
shows a one-year survival advantage of these treatments (39 ± 14%) vs. the historical controls
(0%) (HR = 0.42, 95%CI = 0.18–0.99, p = 0.038).
Discussion
Given many parallels between classical autoimmune syndromes and IPF [3–21,44–46], we hy-
pothesized specific treatments that reduce autoantibodies might also benefit AE-IPF patients.
No inference can yet be drawn as to whether or not autoimmunity, defined by the presence of
autoantibodies [7–17] and autoreactive T-cells,[8,12,13] is a primary cause of the IPF, or is in-
stead a “secondary” response that develops subsequent to a distinct initial injury[43,47,48] or
other dysfunctional consequence of aging (e.g., immunosenescence).[49,50] Nonetheless, the
favorable effects of focused autoantibody-reduction therapies in many of the trial subjects here
are at least an indication that autoantibodies might play a role in AE-IPF [3–21].
Among these therapies, TPE rapidly reduces circulating autoantibodies,[40,41,51] and was
employed here to achieve swift effects in the very rapidly progressing patients. Since this was a
novel therapy for AE-IPF, the initial protocol regimen of five TPE (used in Subjects #1–7) was
predicated on a conservative a priori consideration that aimed to balance the potential to show
some clinical effects, while minimizing the risks and expenses of a wholly untested modality.
While TPE rapidly reduces autoantibodies in the circulation, however, the majority of immu-
noglobulins at any given moment are localized in extravascular tissue and are inaccessible to
Fig 3. Radiographic Changes with Experimental Treatment. In addition to better lung function and gas
exchange, experimental treatments frequently improved the chest radiographs (CXR) of these subjects. a)
Pretreatment CXR of Subject #5 during relapse shows diffuse infiltrates; b.) Radiographic improvement (and
extubation) of this subject to 2nd TPE series. c.) CXR of Subject #7 immediately prior to treatment and d.) after
first three TPE. These (and other) radiographic and clinical improvements in the subject population were not
attributable to changes in intravascular volume status or infection.
doi:10.1371/journal.pone.0127771.g003
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removal by plasma filtration.[41] These extravascular autoantibodies subsequently re-equili-
brate down concentration gradients back into the circulation after TPE treatments, but this is
rate-limited, and significant depletion of total body autoantibodies typically requires numerous
treatments over several days. Thus, clinical relapses are common after therapy of other life-
threatening autoantibody diseases when TPE is terminated prematurely, and effective manage-
ment of these patients often requires far more than five treatments. Given the absence of bene-
fit in Subject #1, in whom autoantibody titers were unaffected by five TPE, as well as the
favorable responses to additional plasma exchanges of two relapsing subjects (#5 and #7), a
greater number of TPE treatments was administered in later subjects (#8–11), with seemingly
more prolonged benefit (Fig 6B).
The present data indicate clinical responses of AE-IPF patients to TPE may correlate with
reductions of pre-treatment autoantibody titers (Fig 4B). In contrast, the absence of an associa-
tion between experimental treatments and MMP7 concentrations, or correlations between the
latter and clinical courses, indicates the patient responses are not simply attributable to TPE re-
moval of circulating [non-autoantibody] injury mediators (Fig 5). Moreover, TPE effects on
concentrations of circulating cytokines, proteases, and other mediators are known to be tran-
sient,[40,41] and cannot plausibly account for the prolonged remissions of many trial subjects.
The duration of benefit following a TPE course is ultimately limited due to the continued
antibody production of autoreactive B-cell clones. Accordingly, TPE was supplemented with
rituximab, a cytolytic, anti-B-cell chimeric murine-human monoclonal antibody with proven
efficacy in many other autoantibody-mediated diseases,[36–39]. The onset of rituximab effects
on circulating autoantibodies may be delayed for weeks after administration, however, which
Fig 4. Anti-HEp-2 Autoantibodies in Trial Patients. A.) Indirect Immuno-fluorescence Assays (IFA). a.)
Pretreatment anti-HEp-2 autoantibodies were present at plasma titrations of 1:80 in Subject #6. b.)
Autoantibodies were diminished immediately following his TPE treatment (image here at 1:20 titration). c.)
Normal plasma control specimen (1:20 titration). B.) IFA Titers. Anti-HEp-2 autoantibody titers were
determined in the first eight subjects. Titers were reduced following the initial TPE series in all except Subject
#1 (dotted line, solid circles), who was also the only subject among these that did not have a beneficial
clinical response.
doi:10.1371/journal.pone.0127771.g004
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would seem to preclude solo therapy with this agent in rapidly progressive AE-IPF patients
who would almost certainly die in the meantime.
Acute reductions of circulating immunoglobulins by TPE may also remove Fc-receptor-me-
diated feedback inhibition of the autoreactive B-cells that escape depletion therapies (e.g., ritix-
umab).[51] These lymphocytes can consequently increase their production of deleterious
autoantibodies, resulting in rapid rebounds of autoantibody concentrations back to or even
greater than pre-treatment levels. IVIG is widely used in the management of other serious au-
toimmune disorders, as an adjunct with TPE and/or rituximab, to mitigate autoantibody re-
bound and/or provide additional immunomodulatory effects.[51,52] IVIG but was not
employed in the first series of subjects, again due to our initial bias for conservatism given the
novelty of this treatment approach for AE-IPF.
Whether the more consistently prolonged response of the latest subject cohort (Fig 6B) is
due to the use of a greater number of initial TPE (nine treatments) or is instead attributable to
the addition of IVIG (or synergism between the two modalities) awaits additional study. The
appropriate role of steroids as an adjunct to the more specific autoantibody-focused treatments
similarly cannot be ascertained by the present study. Steroids have no known efficacy in
AE-IPF, but for practical purposes are standard of care, given the absence of any known effec-
tive treatment for this syndrome, and despite the propensity of these agents for causing infec-
tious and metabolic complications.[1,2]
There are several limitations of this study. This was a pilot, open-label trial of an unprece-
dented regimen for a highly lethal disease and, as such, included only small numbers of subjects
and historical controls. Moreover, the trial regimen evolved to more aggressive therapy in later
Fig 5. Matrix Metalloproteinase 7 (MMP7). PlasmaMMP7 levels did not appear to consistently decrease
with TPE, nor correlate with clinical responses. In particular, three subjects (#3,4,7, open circles, dotted lines)
had increases or no changes of MMP7 levels from pretreatment values despite having prolonged
clinical remissions.
doi:10.1371/journal.pone.0127771.g005
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patients after observing early relapses among some of the first subject cohort. Our desire to
provide what increasingly appeared to be potentially life-saving therapy for our later patients
overrode concerns for conducting a “clean” experiment using an unchanging and seemingly
suboptimal initial medical intervention that had been designed without prior experience, and
had been biased for conservatism. This study was intended to gain incremental insights rele-
vant to a novel approach for therapy of extremely-ill patients, for whom we also had [even
greater] responsibilities as medical care providers. It was not designed to result in the definitive
evidence of a Phase III trial.
Despite these short-comings, the often striking and unprecedented results of the pilot trial
are an encouraging indication that this highly morbid and heretofore untreatable syndrome
may be amenable, at least in some cases, to specific autoantibody-targeted therapies. Although
there is little reason to believe these modalities will reverse the underlying chronic lung fibrosis
of the subjects, the development of therapies that reduce discomfort and extend lives of termi-
nally-ill patients is still laudable, and the goal of considerable effort in other disciplines (e.g.,
oncology). AE-IPF patients are also often too severely-ill at their presentation to undergo de
Fig 6. Survival Comparisons. A.) Survival in the aggregate trial subject population (n = 11) was greater than
among historical control AE-IPF patients (n = 20). Cross hatches and numbers in parentheses denote
censored observations. Lung transplantation censoring is denoted with “T”. B.) Clinical responses may be
more durable and survival may be further enhanced among the later trial subjects (n = 4) treated with a more
aggressive regimen of autoantibody-targeted modalities (9 initial TPE + rituximab + IVIG).
doi:10.1371/journal.pone.0127771.g006
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novo lung transplantation evaluations (e.g. cardiac catheterizations, colonoscopies, swallow
studies, etc.), or survive long enough for a donor organ to become available. Thus, clinical im-
provements effected by these treatments may also be a useful “bridge to transplantation”, as
they were here for Subject #7 and may yet be for Subject #9 (Table 2).
We believe these initial results justify subsequent incremental studies of autoantibody-re-
duction therapies in AE-IPF patients. These could include trials with concurrent, conventional-
ly-treated randomized control subjects, in order to more conclusively prove the effectiveness of
autoantibody-targeted interventions. Further studies could also refine treatment regimens, and
evaluate the utility of longitudinal autoantibody measures to personalize these treatments.
Given minimal advances in the management of IPF, which remains a highly morbid and al-
most invariably fatal disorder despite decades of intense investigation,[1,2] objective consider-
ations of novel pathogenic paradigms and treatments seem especially warranted.
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